MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility

Carcinogenesis

Volumn 32, Issue 8, 2011, Pages 1133-1142

  Polański, Radosław ^a   Maguire, Maria ^a   Nield, Paul C ^a   Jenkins, Rosalind E ^a   Kevin Park, B ^a   Krawczyńska, Karolina ^a   Devling, Timothy ^a   Ray sinha, Arpita ^a   Rubbi, Carlos P ^a   Vlatković, Nikolina ^a   Boyd, Mark T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NON METASTATIC CELL 2 PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE; PROTEIN; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CATALYSIS; CELL ACTIVITY; CELL LYSATE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA LIBRARY; DNA SEQUENCE; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; KIDNEY CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; UPREGULATION;

EID: 79961174425     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr070     Document Type: Article

References (57)

1. Iwakuma,T. et al. (2003) MDM2, an introduction. Mol. Cancer Res., 1, 993-1000.
2. Ganguli,G. et al. (2003) p53-independent functions of MDM2. Mol. Cancer Res., 1, 1027-1035.
3. Sigalas,I. et al. (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2, 912-917.
4. Lundgren,K. et al. (1997) Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11, 714-725.
5. Jones,S.N. et al. (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl Acad. Sci. USA., 95, 15608-15612.
6. Kannemeier,C. et al. (2007) The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance. Mol. Biol. Cell., 18, 2367-2377.
7. Maguire,M. et al. (2008) MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res., 68, 3232-3242.
8. Haitel,A. et al. (2000) mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res., 6, 1840-1844.
9. Ikeguchi,M. et al. (2002) Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am. J. Clin. Oncol., 25, 454-459.
10. Lu,M.L. et al. (2002) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and arraybased methods. Clin. Cancer Res., 8, 171-179.
11. Osman,I. et al. (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res., 5, 2082-2088.
12. Toledo,F. et al. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer, 6, 909-923.
13. Rayner,K. et al. (2008) Discovery of NM23-H2 as an estrogen receptor beta-associated protein: role in estrogen-induced gene transcription and cell migration. J. Steroid Biochem. Mol. Biol., 108, 72-81.
14. Miyazaki,H. et al. (1999) Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin. Cancer Res., 5, 4301-4307.
15. Wang,S.P. et al. (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol., 11, 694-704.
16. Yang,J.Y. et al. (2006) MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell. Biol., 26, 7269-7282.
17. Boissan,M. et al. (2005) Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J. Natl Cancer Inst., 97, 836-845.
18. Rhodes,D.R. et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia, 9, 166-180.
19. Vlatkovic,N. et al. (2000) MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon. Nucleic Acids Res., 28, 3581-3586.
20. Warburton,H.E. et al. (2005) p53 regulation and function in renal cell carcinoma. Cancer Res., 65, 6498-6503.
21. Polanski,R. et al. (2010) MDM2 promotes cell motility and invasiveness through a RING-finger independentmechanism. FEBS Lett., 584, 4695-4702.
22. Brady,M. et al. (2005) Regulation of p53 and MDM2 activity by MTBP. Mol. Cell. Biol., 25, 545-553.
23. Dignam,J.D. et al. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11, 1475-1489.
24. Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
25. Thompson,C.C. et al. (2007) Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut, 56, 95-106.
26. Arya,A.K. et al. (2010) Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br. J. Cancer, 103, 186-195.
27. Boissan,M. et al. (2009) The mammalian Nm23/NDPK family: from metastasis control to cilia movement. Mol. Cell. Biochem., 329, 51-62.
28. Boyd,M.T. et al. (2000) A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J. Biol. Chem., 275, 31883-31890.
29. Meek,D.W. et al. (2003) Posttranslational modification of MDM2. Mol. Cancer Res., 1, 1017-1026.
30. Levit,M.N. et al. (2002) Interactions between Escherichia coli nucleosidediphosphate kinase and DNA. J. Biol. Chem., 277, 5163-5167.
31. Postel,E.H. et al. (2002) Structure-based mutational and functional analysis identify human NM23-H2 as a multifunctional enzyme. Biochemistry, 41, 6330-6337.
32. Kantor,J.D. et al. (1993) Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res., 53, 1971-1973.
33. Leone,A. et al. (1991) Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65, 25-35.
34. Noon,A.P. et al. (2010) p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer, 116, 780-790.
35. Brown,D.R. et al. (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17, 2513-2525.
36. Lascu,L. (2000) The nucleoside diphosphate kinases 1973-2000. J. Bioenerg. Biomembr., 32, 213-214.
37. Palmieri,D. et al. (2006) Translational approaches using metastasis suppressor genes. J. Bioenerg. Biomembr., 38, 151-161.
38. Steeg,P.S. (2004) Perspectives on classic article: metastasis suppressor genes. J. Natl Cancer Inst., 96, E4.
39. Gilles,A.M. et al. (1991) Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J. Biol. Chem., 266, 8784-8789.
40. Urano,T. et al. (1992) Molecular cloning and functional expression of the second mouse nm23/NDP kinase gene, nm23-M2. FEBS Lett., 309, 358-362.
41. Jenkinson,S.R. et al. (2004) S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis. Br. J. Cancer, 90, 253-262.
42. McDermott,W.G. et al. (2008) Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth. Clin. Exp. Metastasis, 25, 131-138.
43. Nakagawa,Y. et al. (1998) Prognostic value of nm23 protein expression in renal cell carcinomas. Oncology, 55, 370-376.
44. Ljungberg,B. et al. (1999) Clinical significance of nm23 expression in renal cell carcinoma. Urol. Res., 27, 103-107.
45. Bosnar,M.H. et al. (1997) Loss of heterozygosity of the nm23-H1 gene in human renal cell carcinomas. J. Cancer Res. Clin. Oncol., 123, 485-488.
46. Leone,A. et al. (1991) Somatic allelic deletion of nm23 in human cancer. Cancer Res., 51, 2490-2493.
47. Fang,S. et al. (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 275, 8945-8951.
48. Baba,H. et al. (1995) Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res., 55, 1977-1981.
49. MacDonald,N.J. et al. (1993) A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J. Biol. Chem., 268, 25780-25789.
50. MacDonald,N.J. et al. (1996) Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J. Biol. Chem., 271, 25107-25116.
51. Postel,E.H. et al. (2009) Double knockout Nme1/Nme2 mouse model suggests a critical role for NDP kinases in erythroid development. Mol. Cell. Biochem., 329, 45-50.
52. Hippe,H.J. et al. (2009) The interaction of nucleoside diphosphate kinase B with Gbetagamma dimers controls heterotrimeric G protein function. Proc. Natl Acad. Sci. USA, 106, 16269-16274.
53. Horak,C.E. et al. (2007) Nm23-H1 suppresses tumor cell motility by downregulating the lysophosphatidic acid receptor EDG2. Cancer Res., 67, 7238-7246.
54. Noon,A.P. et al. Combined p53 & MDM2 biomarker analysis demonstrates a unique pattern of expression associated with poor prognosis in renal cell carcinoma patients undergoing radical nephrectomy. Br. J. Urol. Int in press.
55. Gurova,K.V. et al. (2004) p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res., 64, 1951-1958.
56. Carroll,V.A. et al. (2008) Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res., 68, 545-552.
57. Roberts,A.M. et al. (2009) Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res., 69, 9056-9064.